• RBC Capital downgraded Inspire Medical Systems, Inc. (NYSE: INSP) from "Outperform" to "Sector Perform" with the stock priced at $81.33.
• Baillie Gifford & Co. reduced its stake in Inspire Medical by 2.7%, influencing possibly the downgrade decision.
• Despite the downgrade, Texas Permanent School Fund Corp and Nordea Investment Management AB showed increased interest in INSP, indicating confidence in its future.

Inspire Medical Systems, Inc. (NYSE: INSP) is a company that specializes in innovative medical solutions, particularly for sleep apnea. The company has been a significant player in the medical device industry, offering alternatives to traditional treatments. However, on January 26, 2026, RBC Capital downgraded INSP from an "Outperform" to a "Sector Perform" rating, with the stock priced at $81.33 at the time.

Baillie Gifford & Co., a major shareholder, recently reduced its stake in Inspire Medical by 2.7%, selling 29,538 shares. This reduction leaves them with 1,084,350 shares, representing 3.67% of the company, valued at $80.5 million. This move might have influenced RBC Capital's decision to downgrade the stock.

Despite the downgrade, other investors are showing interest in INSP. Texas Permanent School Fund Corp increased its holdings by 42.2%, now owning 40,042 shares valued at $5.2 million. Additionally, Nordea Investment Management AB acquired a new position valued at approximately $1.6 million, indicating confidence in the company's future.

The stock price of INSP is currently $81.33, reflecting a 2.43% increase or $1.93. The stock has fluctuated between $78.17 and $81.76 today. Over the past year, it reached a high of $203.12 and a low of $70.77, showing significant volatility. The market capitalization stands at approximately $2.41 billion.

The trading volume for INSP on the NYSE is 1,084,065 shares, indicating active investor interest. Despite the recent downgrade by RBC Capital, the stock's performance and investor activity suggest that Inspire Medical Systems remains a company to watch in the medical device sector.